Published by Josh White on 27th November 2024
(Sharecast News) - Faron Pharmaceuticals announced promising interim phase two results from its 'BEXMAB' trial on Wednesday, targeting relapsed or refractory myelodysplastic syndrome (r/r MDS) patients.
URL: http://www.digitallook.com/dl/news/story/34717961/...